Blood Thinner Eliquis Results In Bleed Injuries in Virginia

Blood thinner Eliquis (also known as Apixaban) has been linked to causing uncontrolled gastrointestinal or intracranial bleeding in patients who were taking the drug. Eliquis has been prescribed to control clots related to atrial fibrillation. The drug has also been used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Other injuries from Eliquis include rectal bleeding, intestinal bleeding and brain hemorrhaging. Other drugs included in this new group of anticoagulants called direct thrombin inhibitors are Pradaxa, Xarelto, Zontivity and Savaysa.

Contact Us for a Free Case Evaluation

Allen & Allen is currently investigating cases on behalf of injured users. If you or one of your loved ones has experienced uncontrolled bleeding while using the prescription drug Eliquis, contact the attorneys at Allen & Allen online or by calling 1-866-388-1307.

Details on Eliquis

Patients using blood thinners typically use an INR monitor and manage their drug dosage with the help of healthcare professionals. Eliquis does not require continual INR monitoring, although patients have a wide range of responses to blood thinners.

Eliquis is in the same same category of drugs as Pradaxa and Xarelto. Pfizer and Bristol-Myers Squibb have touted Eliquis as more convenient than Coumadin, a blood thinner which has a proven safety record going back 60 years. However, unlike Coumadin, there is no reversal agent for Eliquis, leading to uncontrolled bleeds.

Eliquis is an anticoagulant that works by inhibiting Factor Xa, one of the basic factors in bleeding and clotting.

About The Author: Jason Konvicka is a partner with Allen & Allen in Richmond, Virginia. During his 20+ year career he has achieved numerous record-setting jury verdicts and substantial settlements on behalf of his clients. Outside of the courtroom, Jason is highly involved with the Virginia Trial Lawyers Association and currently serves on its Board of Governors as Vice President.